Bionano Genomics (NASDAQ:BNGO) Releases Earnings Results, Beats Estimates By $0.03 EPS

Bionano Genomics (NASDAQ:BNGO) announced its earnings results on Monday. The company reported ($0.64) EPS for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.03, FiscalAI reports. The business had revenue of ($6.67) million for the quarter, compared to analysts’ expectations of $7.55 million. Bionano Genomics had a negative net margin of 106.58% and a negative return on equity of 73.27%.

Here are the key takeaways from Bionano Genomics’ conference call:

• Q2 revenue rose 21% year over year to $8.2 million, exceeding guidance, while consumable revenue increased 30% and flow-cell sales reached a record 9,219 units, up 27%. Growth was driven primarily by higher utilization among existing clinical customers.
• Bionano raised the low end of its 2026 revenue outlook to $31 million–$33 million and initiated Q3 guidance of $8.2 million–$8.6 million. Management cited accelerating clinical adoption, reimbursement progress, and international growth as key drivers.
• Demand for nanochannel array flow cells continues to exceed manufacturing capacity, with the company carrying a backlog. Supply constraints led management to leave the high end of full-year guidance unchanged while it works to expand production by mid-to-late Q4.
• Adjusted gross margin reached a quarterly record of 53%, up from 52% a year ago, while operating expenses declined slightly. The company also fully retired its senior secured convertible debt, although ending cash and available securities totaled $10.4 million with runway expected only into at least Q1 2027.
• Bionano reported expanding clinical evidence for optical genome mapping, including a 91-case T-ALL study in which OGM detected abnormalities in 97.8% of cases versus 55% for conventional karyotyping. The company is also targeting a Q4 2026 launch of an Ionic workflow that interfaces directly with OGM and long-read sequencing sample preparation.

Bionano Genomics Stock Performance

NASDAQ BNGO traded down $0.02 during trading hours on Wednesday, hitting $1.17. 23,752 shares of the stock were exchanged, compared to its average volume of 225,724. The company has a quick ratio of 1.59, a current ratio of 1.84 and a debt-to-equity ratio of 0.09. The company has a market cap of $13.47 million, a price-to-earnings ratio of -0.39 and a beta of 1.63. Bionano Genomics has a 12-month low of $1.00 and a 12-month high of $5.50. The stock has a 50-day moving average of $1.15 and a 200 day moving average of $1.19.

Wall Street Analyst Weigh In

A number of research analysts have commented on BNGO shares. Weiss Ratings restated a “sell (e+)” rating on shares of Bionano Genomics in a research note on Wednesday, July 29th. Wall Street Zen upgraded Bionano Genomics to a “hold” rating in a research report on Saturday, June 13th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $6.00.

Institutional Trading of Bionano Genomics

Hedge funds have recently modified their holdings of the business. Carret Asset Management LLC grew its holdings in Bionano Genomics by 76.4% during the fourth quarter. Carret Asset Management LLC now owns 44,100 shares of the company’s stock worth $67,000 after acquiring an additional 19,100 shares during the period. DRW Securities LLC acquired a new position in shares of Bionano Genomics during the 4th quarter worth $258,000. Geode Capital Management LLC increased its holdings in shares of Bionano Genomics by 148.8% in the 4th quarter. Geode Capital Management LLC now owns 66,766 shares of the company’s stock valued at $102,000 after purchasing an additional 39,928 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in shares of Bionano Genomics in the fourth quarter valued at about $57,000. Finally, Jane Street Group LLC acquired a new stake in shares of Bionano Genomics in the fourth quarter valued at about $34,000. 11.35% of the stock is owned by institutional investors and hedge funds.

About Bionano Genomics

Bionano Genomics, Inc (NASDAQ: BNGO) develops and commercializes high‐resolution genome analysis tools designed to map structural variants and large‐scale genomic rearrangements. At the core of its technology is the Saphyr® optical genome mapping system, which uses nanochannel arrays to linearize megabase‐length DNA molecules, proprietary fluorescent labeling reagents to highlight specific sequence motifs, and advanced image processing software to detect structural changes with high sensitivity.